guest ::
| Home > Publications database > CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. > print |
| Home > Publications database > CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. > print |
| 001 | 285250 | ||
| 005 | 20240229155105.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ccell.2023.08.008 |2 doi |
| 024 | 7 | _ | |a pmid:37683639 |2 pmid |
| 024 | 7 | _ | |a 1535-6108 |2 ISSN |
| 024 | 7 | _ | |a 1878-3686 |2 ISSN |
| 024 | 7 | _ | |a altmetric:153903802 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-02285 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Miao, Beiping |0 P:(DE-He78)b5b786a7a28d851956ba90aa9451887a |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1. |
| 260 | _ | _ | |a New York, NY |c 2023 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1699353326_10419 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a DKFZ-ZMBH Alliance / #EA:D250#LA:D250# |
| 520 | _ | _ | |a The dysregulated expression of immune checkpoint molecules enables cancer cells to evade immune destruction. While blockade of inhibitory immune checkpoints like PD-L1 forms the basis of current cancer immunotherapies, a deficiency in costimulatory signals can render these therapies futile. CD58, a costimulatory ligand, plays a crucial role in antitumor immune responses, but the mechanisms controlling its expression remain unclear. Using two systematic approaches, we reveal that CMTM6 positively regulates CD58 expression. Notably, CMTM6 interacts with both CD58 and PD-L1, maintaining the expression of these two immune checkpoint ligands with opposing functions. Functionally, the presence of CMTM6 and CD58 on tumor cells significantly affects T cell-tumor interactions and response to PD-L1-PD-1 blockade. Collectively, these findings provide fundamental insights into CD58 regulation, uncover a shared regulator of stimulatory and inhibitory immune checkpoints, and highlight the importance of tumor-intrinsic CMTM6 and CD58 expression in antitumor immune responses. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 700 | 1 | _ | |a Hu, Zhaoqing |0 P:(DE-He78)9465b7d096574a9f1f1691e2fd17db93 |b 1 |e First author |u dkfz |
| 700 | 1 | _ | |a Mezzadra, Riccardo |b 2 |
| 700 | 1 | _ | |a Hoeijmakers, Lotte |b 3 |
| 700 | 1 | _ | |a Fauster, Astrid |b 4 |
| 700 | 1 | _ | |a Du, Shangce |0 P:(DE-He78)842f32f9066384840481c90552ab2cff |b 5 |u dkfz |
| 700 | 1 | _ | |a Yang, Zhi |b 6 |
| 700 | 1 | _ | |a Sator-Schmitt, Melanie |0 P:(DE-He78)2119821cf3458781f06157c7aeecba8b |b 7 |u dkfz |
| 700 | 1 | _ | |a Engel, Helena |0 P:(DE-He78)1a89b3d8ddc335a4c010ef9d5efabc7a |b 8 |u dkfz |
| 700 | 1 | _ | |a Li, Xueshen |b 9 |
| 700 | 1 | _ | |a Broderick, Caroline |b 10 |
| 700 | 1 | _ | |a Jin, Guangzhi |b 11 |
| 700 | 1 | _ | |a Gomez-Eerland, Raquel |b 12 |
| 700 | 1 | _ | |a Rozeman, Lisette |b 13 |
| 700 | 1 | _ | |a Lei, Xin |b 14 |
| 700 | 1 | _ | |a Matsuo, Hitoshi |0 P:(DE-He78)3be9a4b1ad5dc609e4b60c04de3f9f4d |b 15 |u dkfz |
| 700 | 1 | _ | |a Yang, Chen |0 P:(DE-He78)8b693edfb7c78bb156cc92812eec1c55 |b 16 |u dkfz |
| 700 | 1 | _ | |a Hofland, Ingrid |b 17 |
| 700 | 1 | _ | |a Peters, Dennis |b 18 |
| 700 | 1 | _ | |a Broeks, Annegien |b 19 |
| 700 | 1 | _ | |a Laport, Elke |0 P:(DE-He78)26b012bbbc85e8736a8979469a69d9f6 |b 20 |u dkfz |
| 700 | 1 | _ | |a Fitz, Annika |0 P:(DE-He78)0d8fa784ae0ac78e2f5ef9159c0dc608 |b 21 |u dkfz |
| 700 | 1 | _ | |a Zhao, Xiyue |0 P:(DE-He78)bf4fb8cc5fd36d4f939e03d15dd34019 |b 22 |u dkfz |
| 700 | 1 | _ | |a Mahmoud, Mohamed Abdalla Abdelaziz |0 P:(DE-He78)c64a2551addbc772856c898989c2da62 |b 23 |u dkfz |
| 700 | 1 | _ | |a Ma, Xiujian |0 P:(DE-He78)88de8ba75b18dd92d742eb7eab04a1b3 |b 24 |u dkfz |
| 700 | 1 | _ | |a Sander, Sandrine |0 P:(DE-He78)3c4e3363a68498c72ad042b849e11f3a |b 25 |u dkfz |
| 700 | 1 | _ | |a Liu, Hai-Kun |0 P:(DE-He78)76aeb2431f7458c9261e69c5420390c6 |b 26 |u dkfz |
| 700 | 1 | _ | |a Cui, Guoliang |0 P:(DE-He78)0b7ce76033a6756b91f5bfb12602e20b |b 27 |u dkfz |
| 700 | 1 | _ | |a Gan, Yu |b 28 |
| 700 | 1 | _ | |a Wu, Wei |b 29 |
| 700 | 1 | _ | |a Xiao, Yanling |b 30 |
| 700 | 1 | _ | |a Heck, Albert J R |b 31 |
| 700 | 1 | _ | |a Guan, Wenxian |b 32 |
| 700 | 1 | _ | |a Lowe, Scott W |b 33 |
| 700 | 1 | _ | |a Horlings, Hugo M |b 34 |
| 700 | 1 | _ | |a Wang, Cun |b 35 |
| 700 | 1 | _ | |a Brummelkamp, Thijn R |b 36 |
| 700 | 1 | _ | |a Blank, Christian U |b 37 |
| 700 | 1 | _ | |a Schumacher, Ton N M |b 38 |
| 700 | 1 | _ | |a Sun, Chong |0 P:(DE-He78)ef40d75e5564c492ee57b4262fc016fe |b 39 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1016/j.ccell.2023.08.008 |g Vol. 41, no. 10, p. 1817 - 1828.e9 |0 PERI:(DE-600)2074034-7 |n 10 |p 1817 - 1828.e9 |t Cancer cell |v 41 |y 2023 |x 1535-6108 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:285250 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)b5b786a7a28d851956ba90aa9451887a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)9465b7d096574a9f1f1691e2fd17db93 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)842f32f9066384840481c90552ab2cff |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)2119821cf3458781f06157c7aeecba8b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)1a89b3d8ddc335a4c010ef9d5efabc7a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 15 |6 P:(DE-He78)3be9a4b1ad5dc609e4b60c04de3f9f4d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 16 |6 P:(DE-He78)8b693edfb7c78bb156cc92812eec1c55 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)26b012bbbc85e8736a8979469a69d9f6 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 21 |6 P:(DE-He78)0d8fa784ae0ac78e2f5ef9159c0dc608 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)bf4fb8cc5fd36d4f939e03d15dd34019 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 23 |6 P:(DE-He78)c64a2551addbc772856c898989c2da62 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 24 |6 P:(DE-He78)88de8ba75b18dd92d742eb7eab04a1b3 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 25 |6 P:(DE-He78)3c4e3363a68498c72ad042b849e11f3a |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 26 |6 P:(DE-He78)76aeb2431f7458c9261e69c5420390c6 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 27 |6 P:(DE-He78)0b7ce76033a6756b91f5bfb12602e20b |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 39 |6 P:(DE-He78)ef40d75e5564c492ee57b4262fc016fe |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CANCER CELL : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-24 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-24 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 50 |0 StatID:(DE-HGF)9950 |2 StatID |b CANCER CELL : 2022 |d 2023-10-24 |
| 920 | 2 | _ | |0 I:(DE-He78)D250-20160331 |k D250 |l NWG Krebs-Immunregulation |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)D250-20160331 |k D250 |l NWG Krebs-Immunregulation |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D250-20160331 |k D250 |l NWG Krebs-Immunregulation |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)A240-20160331 |k A240 |l A240 Molekulare Neurogenetik |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)D180-20160331 |k D180 |l NWG Erworbene Immunität und Lymphome |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)D192-20160331 |k D192 |l T-Zell-Metabolismus |x 3 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)D250-20160331 |
| 980 | _ | _ | |a I:(DE-He78)A240-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D180-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D192-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|